Description
Devazepide is a potent and orally active cholecystokinin A(CCK-A) receptor antagonist with IC50 value of 0.26 nM. It is a derivative of benzodiazepine that displays appetite-stimulant effects. It blocks the anorectic response to CCK-8 and increases food intake in rats. It increases appetite and accelerates gastric emptying. It is used as a potential treatment for a variety of gastrointestinal problems including gastroparesis, dyspepsia and gastric reflux. It was developed by Merck Sharp & Dohme and was terminated in clinic phase 2 trials